Skip to main content
Clinical Trials/NCT06906523
NCT06906523Active, not recruitingNot Applicable

Blood Flow Restriction in Older Adults. A Randomised Single-blind Clinical Trial

Universidad Católica San Antonio de Murcia1 site in 1 country18 target enrollmentStarted: March 12, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
18
Locations
1
Primary Endpoint
Change from baseline muscle power after treatment and at four weeks

Study Overview

Brief Summary

Introduction. From the age of 80 onwards, more than 50% of people suffer from sarcopenia. The loss of muscle strength leads to a loss of muscle power, impairing functionality and preventing the correct performance of activities of daily living.

Objective. To analyse the efficacy of blood flow restriction in older adult patients by evaluating changes in the variables muscle power and strength, physical condition and functionality of the lower limbs.

Material and method. Randomised single-blind clinical study. Thirty-six older adults will be recruited and randomised to the experimental and control groups. The intervention will have a duration of 4 weeks, with 2 weekly sessions. The intervention will consist of an intervention by performing 3 quadriceps strength exercises, with a 40% restriction. The primary variable of the study will be muscle power (Sit To Stand 5 times) and the secondary variables will be muscle strength (dynamometry), physical condition (Timed Up and Go) and functionality and autonomy (Barthel index)

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
65 Years to 80 Years (Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Older adults aged 65 to 80 years
  • •Independent for standing and walking with the help of assistive devices such as cane and walker
  • •Both genders
  • •Normotensive or hypertensive with controlled BP (systolic blood pressure <140 mmHg)
  • •Sign the informed consent form.

Exclusion Criteria

  • •People dependent for the performance of activities of daily living.
  • •People with cognitive impairments that limit the performance of the intervention or assessments.
  • •Persons undergoing total hip or knee arthroplasty
  • •Persons receiving physiotherapy treatment at the time of the study
  • •History of deep vein thrombosis (DVT) or pulmonary embolism
  • •History of myocardial infarction or stroke

Arms & Interventions

No intervention

No Intervention

Patients included in the control group will not receive any intervention, maintaining their activities of daily living in the same way as before the study.

Blood flow restriction

Experimental

An exercise protocol will be applied to work on lower limb strength in extension, with the application of BFR, with two 30-minute sessions per week for four weeks. The exercise protocol, based on previous studies in older adults, will consist of three exercises: climbing on a step, knee extension from a seated position and sitting down and getting up from a chair.

Intervention: Blood flow restriction training (Other)

Outcomes

Primary Outcomes

Change from baseline muscle power after treatment and at four weeks

Time Frame: Screening visit, within the first seven days after treatment and four weeks follow-up visit

Muscle power will be assessed with the Sit To Stand 5 times. This tool consists of getting up and sitting down from a chair five times. This instrument has shown high reliability (CCI= 0.95). The unit of measurement is time in seconds, where the shorter the time the greater the muscle power

Secondary Outcomes

  • Change from baseline muscle strength after treatment and at four weeks(Screening visit, within the first seven days after treatment and four weeks follow-up visit)
  • Change from baseline physical condition after treatment and at four weeks(Screening visit, within the first seven days after treatment and four weeks follow-up visit)
  • Change from baseline functionality after treatment and at four weeks(Screening visit, within the first seven days after treatment and four weeks follow-up visit)

Investigators

Sponsor
Universidad Católica San Antonio de Murcia
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Rubén Cuesta-Barriuso, PhD

Principal Investigator

University of Oviedo

Study Sites (1)

Loading locations...

Similar Trials